Is there still a role for nuchal translucency measurement in the changing paradigm of first trimester screening?
Francesca BardiPien BosschieterJoke VerheijAttie GoMonique HaakMireille BekkerEsther SikkelAudrey CoumansEva PajkrtCaterina M BilardoPublished in: Prenatal diagnosis (2019)
Although cfDNA is superior to the combined test, especially for the detection of trisomy 21, 34% of the congenital abnormalities occurring in fetuses with increased NT may remain undetected in the first trimester of pregnancy, unless cfDNA is used in combination with fetal sonographic assessment, including NT measurement.